AstraZeneca has upped its revenue expectations following a strong second quarter, saying that sales of newer drugs will offset a major patent expiry and the impact of Brexit.
The FDA has approved a second biosimilar of Roche’s leukaemia drug Rituxan, along with yet another biosimilar of AbbVie’s inflammatory diseases blockbuster Humira.
NICE is to review how it develops guidance on drugs, focusing on issues such as modifiers used in decision making and dealing with uncertainties in evidence.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
